| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-07-14 |
| タイトル |
|
|
タイトル |
Evaluation of the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis in Nairobi, Kenya |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Orina, Fred
Hikone, Mayu
Saito, Nobuo
Ong’ang’o, Jane
Nyerere, Andrew
Songoro, Edinah
Meme, Helen
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Treatment monitoring is important in pulmonary tuberculosis (PTB) management, since prolonged treatment necessitates regular assessments to prevent treatment failure and the emergence of drug-resistant strains. However, the lack of a simple, rapid, and reliable treatment monitoring tool (TMT) remains a major challenge. We evaluated the utility of measuring sputum lipoarabinomannan (LAM) concentration by the PATHFAST TB LAM Ag assay (PHC Corporation, Tokyo, Japan) as a TMT in patients with PTB in Nairobi, Kenya. Methods: We retrospectively analyzed sputum LAM levels via the PATHFAST TB LAM Ag assay from a Nairobi cohort of patients with PTB and compared these results with conventional microbiological tests (acid-fast bacilli [AFB] smear microscopy; mycobacterial growth indicator tube [MGIT] culture). Stored sputum pellets processed with N-acetyl-L-cysteine (NALC)-NaOH were used for LAM measurement. Serial LAM concentrations measured every 2 weeks over an 8-week period were compared across bacterial load categories to assess correlations with AFB smear grades and culture results using the Kruskal–Wallis and Mann–Whitney U tests. Results: The 98 patients included here had a median age of 37 years (Interquartile Range: 27–44). The majority were men (74/98, 75.5%) and the MGIT culture was positive for 89 (90.8%) of them. Patients with elevated baseline LAM concentrations showed a significant reduction in LAM levels with treatment (90% median reduction by week 8), whereas those with low baseline LAM concentrations did not show a declining trend. Sputum LAM levels were significantly higher in culture-positive samples compared to culture-negative samples (23.8 pg/mL vs. 10.8 pg/mL, P < 0.001). Sputum LAM levels showed a significant correlation with AFB smear grades, with median concentrations increasing progressively from 11.3 pg/mL in smear-negative samples to 19.7 pg/mL in scanty/1 + samples, and 46.7 pg/mL in 2 + /3 + samples (P = 0.0001). LAM levels were significantly higher in culture-positive/AFB-positive sputum samples (viable bacilli) than in culture-negative/AFB-positive samples (non-viable bacilli) (P < 0.0001). Conclusion: Our findings revealed that sputum LAM concentration declined during TB treatment, particularly among patients with high baseline levels, and correlated with AFB smear grades and culture results. Additionally, LAM concentrations differed between culture-positive and culture-negative samples among AFB smear-positive samples. Further prospective studies are needed to assess LAM levels as a TMT. |
|
言語 |
en |
| 書誌情報 |
en : Tropical Medicine and Health
巻 53,
号 1,
p. art. no. 89,
発行日 2025-07-01
|
| 出版者 |
|
|
出版者 |
BioMed Central Ltd |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1349-4147 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1186/s41182-025-00771-z |
| 権利 |
|
|
権利情報 |
© The Author(s) 2025. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Tropical Medicine and Health, 53(1), art. no. 89; 2025 |
|
言語 |
en |
TMH53_89.pdf (1.3 MB)
